» Authors » Hans Slabbynck

Hans Slabbynck

Explore the profile of Hans Slabbynck including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 468
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Guiot J, Henket M, Gester F, Andre B, Ernst B, Frix A, et al.
Respir Res . 2025 Jan; 26(1):39. PMID: 39856708
Background: Systemic sclerosis (SSc) is a rare connective tissue disease associated with rapidly evolving interstitial lung disease (ILD), driving its mortality. Specific imaging-based biomarkers associated with the evolution of lung...
2.
Froidure A, Bondue B, Dahlqvist C, Guiot J, Gusbin N, Wirtz G, et al.
Respirology . 2023 Dec; 29(4):304-311. PMID: 38123492
Background And Objective: Real-life data on suspected familial fibrosis, defined as the occurrence of the disease in a patient younger than 50 and/or having at least one relative affected by...
3.
Bosteels C, Van Damme K, De Leeuw E, Declercq J, Maes B, Bosteels V, et al.
Cell Rep Med . 2022 Dec; 3(12):100833. PMID: 36459994
GM-CSF promotes myelopoiesis and inflammation, and GM-CSF blockade is being evaluated as a treatment for COVID-19-associated hyperinflammation. Alveolar GM-CSF is, however, required for monocytes to differentiate into alveolar macrophages (AMs)...
4.
Froidure A, Bondue B, Dahlqvist C, Guiot J, Gusbin N, Wirtz G, et al.
Chest . 2022 Oct; 163(2):358-361. PMID: 36183786
No abstract available.
5.
Wuyts W, Dahlqvist C, Slabbynck H, Schlesser M, Gusbin N, Compere C, et al.
Pulm Ther . 2022 Apr; 8(2):181-194. PMID: 35429319
Introduction: The PROOF registry is a prospective, observational study that aimed to monitor disease progression in a real-world cohort of patients with idiopathic pulmonary fibrosis (IPF). Here, longitudinal quality-of-life (QoL)...
6.
Declercq J, Van Damme K, De Leeuw E, Maes B, Bosteels C, Tavernier S, et al.
Lancet Respir Med . 2021 Nov; 9(12):1427-1438. PMID: 34756178
Background: Infections with SARS-CoV-2 continue to cause significant morbidity and mortality. Interleukin (IL)-1 and IL-6 blockade have been proposed as therapeutic strategies in COVID-19, but study outcomes have been conflicting....
7.
Stylemans D, Van Cauwelaert S, DHaenens A, Slabbynck H
Infect Dis Clin Pract (Baltim Md) . 2021 Sep; 29(5):e305-e306. PMID: 34539164
Eosinopenia was frequently encountered in patients with coronavirus disease 2019 (COVID-19). We describe a case of a 59-year-old man who was treated with high-dose corticosteroids and anti-interleukin 1 receptor antagonist...
8.
Wuyts L, Camerlinck M, De Surgeloose D, Vermeiren L, Ceulemans D, Clukers J, et al.
Br J Radiol . 2021 Feb; 94(1120):20201159. PMID: 33539231
Objectives: To determine whether the revised 2018 ATS/ERS/JRS/ALAT radiological criteria for usual interstitial pneumonia (UIP) provide better diagnostic agreement compared to the 2011 guidelines. Methods: Cohort for this cross-sectional study...
9.
Van Cauwelaert S, Stylemans D, DHaenens A, Slabbynck H, Nieuwendijk R
Acta Clin Belg . 2021 Jan; 77(2):416-420. PMID: 33449840
Introduction: Antisynthetase syndrome (ASSD) is a rare auto-immune condition that can present as interstitial lung disease (ILD) and progress into Acute Respiratory Distress Syndrome (ARDS). Importance: The purpose of this...
10.
Slabbynck H, de Beukelaar T, De Surgeloose D, Van Goethem J, Charels K, Bedert L, et al.
Sarcoidosis Vasc Diffuse Lung Dis . 2020 Jun; 34(3):251-256. PMID: 32476853
Idiopathic dendriform diffuse pulmonary ossification (DPO) is a rare disorder. High resolution CT (HRCT) with appropriate osteoporosis window setting reveals the diagnosis. We report the features of eight patients, of...